Mammogen Appoints Denise DeMan to Lead Board of Directors

Leadership Transformation at Mammogen with Denise DeMan

Mammogen, a pioneering company in predictive health focused on women's health diagnostics, has embarked on a significant leadership change. The company has announced the appointment of Denise "DeeDee" DeMan as the Chairwoman of its Board of Directors. This strategic move signals a vibrant phase of growth and innovation for the company.

DeDee DeMan: A Leader in Life Sciences

Denise DeMan is well-known for her remarkable track record in building strong boards and executive teams within the life sciences sector. As the Founder, Chair, and CEO of Bench International, she brings over fifty years of invaluable experience in placing key directors and executives in esteemed healthcare organizations worldwide. DeMan has played a vital role in shaping the leadership teams responsible for groundbreaking healthcare innovations.

Commitment to Inclusive Governance

Throughout her illustrious career, DeMan has emphasized inclusive governance and executive excellence. Her notable initiatives, including the recognizable Bank of Women, work to ensure diverse voices are present at every level within organizations. This dedication aligns seamlessly with Mammogen’s vision to have women’s perspectives at the forefront of its operations, reflecting a commitment to shaping a more equitable future in healthcare.

Mammogen’s Innovative Solutions

Mammogen stands out with its flagship product, genTRU™. This blood-based early detection test for breast cancer is designed to identify the disease in its earliest stages, ensuring higher treatment success rates. The genTRU™ assay boasts an impressive sensitivity of over 99% and an 89% specificity for Stage I disease. These results are supported by extensive clinical validation and peer-reviewed research.

Pioneering Breast Cancer Screening

As the company gears up for commercialization, the significance of its genTRU™ screening test cannot be overstated. Aimed at addressing a pressing need for effective screening methods, this diagnostic innovation targets over 25 million women in the U.S. who are at risk for breast cancer according to established guidelines.

Message of Confidence from Leadership

Denise DeMan expressed her enthusiasm for joining Mammogen’s leadership at this pivotal moment. She remarked on the company’s readiness to deliver transformative value in an evolving healthcare landscape. DeMan highlighted that Mammogen's integration of validated science and robust leadership makes it uniquely positioned for success as it embarks on the next chapter of its journey.

Strengthening Board Governance

In her new role, DeMan will take charge of Mammogen's board governance strategy, focusing on fortifying the company's standing in the industry as it proceeds toward commercialization. Her wealth of experience and commitment to nurturing effective governance structures will play a critical role in guiding Mammogen through this exciting transition.

About Mammogen

Mammogen is at the forefront of revolutionizing women’s health diagnostics. With an unwavering commitment to early detection and quality-of-life preservation, the company aims to enhance accessibility and diagnostic capabilities through innovative science. Mammogen is proud to be women-built, women-led, and driven by purpose, focusing on delivering accurate solutions to pressing health challenges.

About Bench International

Bench International holds the distinction of being the longest-serving woman-founded executive search firm in the life sciences field. With over 50 years of expertise in advising boards and executive teams, Bench has a remarkable project completion rate and stands out for its commitment to driving innovation and success across the healthcare sector. The firm specializes in various leadership services, ensuring companies thrive in an ever-evolving market.

Frequently Asked Questions

1. Who is Denise "DeeDee" DeMan?

Denise "DeeDee" DeMan is the newly appointed Chairwoman of Mammogen's Board of Directors, bringing extensive experience from Bench International.

2. What is Mammogen's primary product?

Mammogen's flagship product is genTRU™, a blood-based assay for early detection of breast cancer, making a significant impact in women’s health diagnostics.

3. How does genTRU™ work?

The genTRU™ assay detects breast cancer at its earliest stages, demonstrating over 99% sensitivity and 89% specificity for Stage I disease.

4. What is the mission of Mammogen?

Mammogen aims to preserve quality of life through early, accessible health diagnostics powered by cutting-edge scientific advancements.

5. What role will DeMan play at Mammogen?

As Chairwoman, DeMan will guide the board governance strategy and support Mammogen's growth and commercialization efforts in the healthcare sector.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.